Company intelligence / Profile preview

Haidashe Huage Pharmaceutical

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Haidashe Huage Pharmaceutical is a Chinese biotechnology company focused on the development of innovative small molecule therapeutics for metabolic diseases. The company's lead program is HD-101, a novel glucokinase activator (GKA) currently in clinical development for the treatment of type 2 diabetes mellitus. Haidashe Huage aims to address unmet medical needs in the metabolic space by leveraging its expertise in medicinal chemistry and clinical pharmacology. The company operates primarily out of Beijing, focusing on the domestic Chinese market while maintaining standards for global clinical development.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Haidashe Huage Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haidashe Huage Pharmaceutical.

Explore the full profile